Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 3
Locations
Germany
Study Type
Interventional
Intervention
Bisoprolol/Amlodipine (Bisoprolol failed group)
Bisoprolol/Amlodipine (Amlodipine failed group)
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Bisoprolol, Amlodipine, Fixed dose combination (FDC), Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP)
Eligibility Criteria
Inclusion Criteria:
- Essential hypertension not controlled at 5 mg bisoprolol or 5 mg amlodipine at least 4 weeks (definition of not controlled: SBP greater than or equal to (>=) 140 millimeter of mercury (mmHg) with or without DBP >= 90 mmHg)
- Male or female subjects >=18 years of age, without limitation on race
- Medically accepted effective contraception if procreative potential exists (applicable for both male and female subjects until at least 90 days after the last dose of trial treatment)
- Subjects who have signed the informed consent form before any trial related assessment
Exclusion Criteria:
General contraindications of beta-blockers and/or calcium channel blockers
- Previous and concurrent acute heart failure or during episodes of heart failure decompensation requiring intravenous inotropic therapy
- Concurrent cardiogenic shock
- Previous and concurrent second or third degree atrioventricular (AV) block (without a pacemaker)
- Previous and concurrent sick sinus syndrome
- Previous and concurrent sinoatrial block
- Concurrent symptomatic bradycardia
- Concurrent symptomatic hypotension
- Previous and concurrent severe bronchial asthma or chronic obstructive pulmonary diseases
- Previous and concurrent severe peripheral arterial occlusive diseases and Raynaud's syndrome
- Untreated pheochromocytoma
- Concurrent metabolic acidosis
- Known hypersensitivity to bisoprolol, amlodipine, dihydropyridine derivates or to any of the excipients
- Seated pulse rate less than 60 beats per minute (bpm) at screening
- Any other anti-hypertensive drugs (other than bisoprolol and amlodipine) are used within 4 weeks prior to the screening visit
- Use of any enzyme-modifying drugs acting on cytochrome P450 (CYP) 3A4 enzymes via inhibition (such as ketoconazole, itraconazole, ritonavir) or induction (such as rifampicin or hypericum perforatum) within 28 days before Day 1 of the trial
- Other significant disease that in the Investigator's opinion that would exclude the subject from the trial, such as uncontrolled diabetes mellitus, severe liver and/or kidney dysfunction, decompensated cardiac failure
- Any other condition or therapy which in the Investigator's opinion would pose a risk to the subject or interfere with the trial objectives
- Concurrent alcohol and/or drug abuse
- Known hypersensitivity to the trial treatments
- Pregnancy and lactation period. All female subjects with reproductive potential must have a negative pregnancy serum test within the 7 days prior to enrollment
- Known lack of subject compliance
- Legal incapacity or limited legal capacity
- Participation in another clinical trial within the previous 30 days
- Persons directly involved in the execution of the protocol
Sites / Locations
- Please contact the Merck KGaA Communication Center located in
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Bisoprolol failed group
Amlodipine failed group
Arm Description
Subjects who failed monotherapy with bisoprolol 5 milligram (mg) before trial inclusion will be randomized to bisoprolol failed group to receive Bisoprolol/Amlodipine FDC tablet
Subjects who failed monotherapy with amlodipine 5 mg before trial inclusion will be randomized to amlodipine failed group to receive Bisoprolol/Amlodipine FDC tablet.
Outcomes
Primary Outcome Measures
Mean Reduction In Systolic Blood Pressure (SBP) After 18 Weeks of Treatment From Baseline
Baseline was defined as the latest SBP under monotherapy.
Secondary Outcome Measures
Change From Baseline in Diastolic Blood Pressure (DBP) After 18 Weeks of Treatment
Baseline was defined as the latest DBP before study treatment administration.
Percentage of Subjects With Controlled Blood Pressure
Change From Baseline in Heart Rate (HR) After 18 Weeks of Treatment
Baseline was defined as the latest HR before study treatment administration
Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, AEs Leading to Discontinuation and AEs Leading to Death
An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent AEs was AEs that started or worsened in severity on or after the date of first dose of IMP until the end of the study. AEs leading to death and discontinued were also presented.
Full Information
NCT ID
NCT01977794
First Posted
October 31, 2013
Last Updated
January 12, 2017
Sponsor
Merck KGaA, Darmstadt, Germany
1. Study Identification
Unique Protocol Identification Number
NCT01977794
Brief Title
Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension
Official Title
A Randomized, Comparative Trial of Concor AM, a Fixed Dose Combination of Bisoprolol and Amlodipine, on the Treatment of Essential Hypertensive Patients Whose Blood Pressure is Not Well Controlled by Monotherapy of Bisoprolol 5mg or Amlodipine 5mg
Study Type
Interventional
2. Study Status
Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
March 2014 (undefined)
Primary Completion Date
March 2015 (Actual)
Study Completion Date
March 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merck KGaA, Darmstadt, Germany
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a randomized, comparative Phase 3 trial to investigate the efficacy of fixed dose combination (FDC) of bisoprolol and amlodipine in hypertensive subjects (superiority of FDC over monotherapies).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Bisoprolol, Amlodipine, Fixed dose combination (FDC), Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP)
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Bisoprolol failed group
Arm Type
Experimental
Arm Description
Subjects who failed monotherapy with bisoprolol 5 milligram (mg) before trial inclusion will be randomized to bisoprolol failed group to receive Bisoprolol/Amlodipine FDC tablet
Arm Title
Amlodipine failed group
Arm Type
Experimental
Arm Description
Subjects who failed monotherapy with amlodipine 5 mg before trial inclusion will be randomized to amlodipine failed group to receive Bisoprolol/Amlodipine FDC tablet.
Intervention Type
Drug
Intervention Name(s)
Bisoprolol/Amlodipine (Bisoprolol failed group)
Other Intervention Name(s)
Concor AM
Intervention Description
Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure (BP) is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
Intervention Type
Drug
Intervention Name(s)
Bisoprolol/Amlodipine (Amlodipine failed group)
Other Intervention Name(s)
Concor AM
Intervention Description
Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 milligram (mg)/5 mg once daily for 6 weeks. If BP is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
Primary Outcome Measure Information:
Title
Mean Reduction In Systolic Blood Pressure (SBP) After 18 Weeks of Treatment From Baseline
Description
Baseline was defined as the latest SBP under monotherapy.
Time Frame
Baseline, Week 18
Secondary Outcome Measure Information:
Title
Change From Baseline in Diastolic Blood Pressure (DBP) After 18 Weeks of Treatment
Description
Baseline was defined as the latest DBP before study treatment administration.
Time Frame
Baseline, Week 18
Title
Percentage of Subjects With Controlled Blood Pressure
Time Frame
Baseline up to Week 18
Title
Change From Baseline in Heart Rate (HR) After 18 Weeks of Treatment
Description
Baseline was defined as the latest HR before study treatment administration
Time Frame
Baseline, Week 18
Title
Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, AEs Leading to Discontinuation and AEs Leading to Death
Description
An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent AEs was AEs that started or worsened in severity on or after the date of first dose of IMP until the end of the study. AEs leading to death and discontinued were also presented.
Time Frame
Baseline up to Day 127 (end of trial)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Essential hypertension not controlled at 5 mg bisoprolol or 5 mg amlodipine at least 4 weeks (definition of not controlled: SBP greater than or equal to (>=) 140 millimeter of mercury (mmHg) with or without DBP >= 90 mmHg)
Male or female subjects >=18 years of age, without limitation on race
Medically accepted effective contraception if procreative potential exists (applicable for both male and female subjects until at least 90 days after the last dose of trial treatment)
Subjects who have signed the informed consent form before any trial related assessment
Exclusion Criteria:
General contraindications of beta-blockers and/or calcium channel blockers
Previous and concurrent acute heart failure or during episodes of heart failure decompensation requiring intravenous inotropic therapy
Concurrent cardiogenic shock
Previous and concurrent second or third degree atrioventricular (AV) block (without a pacemaker)
Previous and concurrent sick sinus syndrome
Previous and concurrent sinoatrial block
Concurrent symptomatic bradycardia
Concurrent symptomatic hypotension
Previous and concurrent severe bronchial asthma or chronic obstructive pulmonary diseases
Previous and concurrent severe peripheral arterial occlusive diseases and Raynaud's syndrome
Untreated pheochromocytoma
Concurrent metabolic acidosis
Known hypersensitivity to bisoprolol, amlodipine, dihydropyridine derivates or to any of the excipients
Seated pulse rate less than 60 beats per minute (bpm) at screening
Any other anti-hypertensive drugs (other than bisoprolol and amlodipine) are used within 4 weeks prior to the screening visit
Use of any enzyme-modifying drugs acting on cytochrome P450 (CYP) 3A4 enzymes via inhibition (such as ketoconazole, itraconazole, ritonavir) or induction (such as rifampicin or hypericum perforatum) within 28 days before Day 1 of the trial
Other significant disease that in the Investigator's opinion that would exclude the subject from the trial, such as uncontrolled diabetes mellitus, severe liver and/or kidney dysfunction, decompensated cardiac failure
Any other condition or therapy which in the Investigator's opinion would pose a risk to the subject or interfere with the trial objectives
Concurrent alcohol and/or drug abuse
Known hypersensitivity to the trial treatments
Pregnancy and lactation period. All female subjects with reproductive potential must have a negative pregnancy serum test within the 7 days prior to enrollment
Known lack of subject compliance
Legal incapacity or limited legal capacity
Participation in another clinical trial within the previous 30 days
Persons directly involved in the execution of the protocol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical responsible
Organizational Affiliation
Merck KGaA, Darmstadt, Germany
Official's Role
Study Director
Facility Information:
Facility Name
Please contact the Merck KGaA Communication Center located in
City
Darmstadt
Country
Germany
12. IPD Sharing Statement
Citations:
PubMed Identifier
27334671
Citation
Gottwald-Hostalek U, Li L, Montenegro P. Bisoprolol/amlodipine combination therapy improves blood pressure control in patients with essential hypertension following monotherapy failure. Curr Med Res Opin. 2016 Oct;32(10):1735-1743. doi: 10.1080/03007995.2016.1205573. Epub 2016 Jul 4.
Results Reference
derived
Learn more about this trial
Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension
We'll reach out to this number within 24 hrs